Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorWillmann, Jonas
dc.contributor.authorAndratschke, Nicolaus H.
dc.date.accessioned2023-11-21T10:44:21Z
dc.date.available2023-11-21T10:44:21Z
dc.date.issued2023-07-27
dc.description.abstractBackground Reirradiation is a potentially useful option for many patients with recurrent cancer, aiming at cure or symptom palliation, depending on disease/recurrence type and stage. The purpose of this follow-up study to a previous review from 2016 was to summarize all recently published randomized trials. Points of interest again included identifcation of methodological strengths and weaknesses, practice-changing results, and open questions.<p> <p>Material and methods Systematic review of trials published between 2015 and February 2023. <p>Results We reviewed 7 additional trials, most of which addressed reirradiation of head and neck or brain tumours. The median number of patients was 60. Mirroring the previous review, trial design, primary endpoints and statistical hypotheses varied widely. The updated results only impact on decision making for reirradiation of nasopharynx cancer and glioma. Patients with one of these diseases, as well as other head and neck cancers, may benefit from reirradiation-induced local control, e.g. in terms of progression-free survival. For the first time, hyperfractionated radiotherapy emerged as preferred option for recurrent, inoperable nasopharynx cancer. Despite better therapeutic ratio with hyperfractionation, serious toxicity remains a concern after high cumulative total doses. Randomized trials are still lacking for prostate cancer and other sites. <p>Conclusion Multicentric randomized trials on reirradiation are feasible and continue to refine the current standard of care for recurrent disease after previous radiotherapy. Ongoing prospective studies such as the European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer (ESTRO-EORTC) observational cohort ReCare (NCT: NCT03818503) will further shape the clinical practice of reirradiation.en_US
dc.identifier.citationNieder, Willmann, Andratschke. Prospective randomized clinical studies involving reirradiation: update of a systematic review. Strahlentherapie und Onkologie (Print). 2023;199(9):787-797en_US
dc.identifier.cristinIDFRIDAID 2178046
dc.identifier.doi10.1007/s00066-023-02118-1
dc.identifier.issn0179-7158
dc.identifier.issn1439-099X
dc.identifier.urihttps://hdl.handle.net/10037/31836
dc.language.isoengen_US
dc.publisherSpringer Natureen_US
dc.relation.journalStrahlentherapie und Onkologie (Print)
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titleProspective randomized clinical studies involving reirradiation: update of a systematic reviewen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)